Crossmark

STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma

Published Online: 2015-05-01

Published Print: 2015-06

Authors

Marozin, S

Altomonte, J

Muñoz-Álvarez, K A

Rizzani, A

De Toni, E N

Thasler, W E

Schmid, R M

Ebert, O
License Information

Text and Data Mining valid from 2015-05-01

Version of Record valid from 2015-05-01
More Information

Article History

Received: 15 February 2015

Revised: 27 March 2015

Accepted: 28 March 2015

First Online: 1 May 2015

Competing interests

: The authors declare no conflict of interest.

Document is current